Noah J. Moss

Drafting a journal-style article that proposes some antitrust enforcement concerns the FTC and DoJ may face in the coming years as it relates to maintaining fair competition in the developing market for biological therapeutics, e.g., anticompetitive settlement agreements and litigation practices. This article is the continuation of a project I completed while studying for an LL.M (2014, magna cum laude) at Fordham.

Worked as an in-house attorney at a multinational chemical company on diverse projects related to corporate compliance (and other tasks related to legal support for General Counsel); served as lead counsel on two shareholder derivative litigation cases involving breach of an LLC operating agreement and breach of fiduciary duties; advise small business entrepreneurs on intellectual property and fund-raising strategy.

Worked as a first year associate on patent litigation involving several anti-abuse prodrugs; co-authored amicus briefs related to intellectual property for submission before both the Federal Circuit and U.S. Supreme Court; worked as a contract attorney for an AmLaw100 firm in NYC representing first-wave pharma and biotech firms; extensive academic and writing work related to intellectual property law and policy; Of Counsel for Patent Counsel Group, LLP; business consulting for the entrepreneur.

Specialize in the constitutional underpinnings of intellectual property law and their associated applications.